×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ZBIO – zenas biopharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ZBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/21
02:38 pm
zbio
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]
Medium
Report
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch [Yahoo! Finance]
3/21
01:31 am
zbio
Zenas BioPharma (ZBIO) was downgraded by Wall Street Zen from "hold"
Medium
Report
Zenas BioPharma (ZBIO) was downgraded by Wall Street Zen from "hold"
3/19
06:20 am
zbio
Zenas BioPharma (ZBIO) was downgraded by Zacks Research from "hold" to "strong sell".
Low
Report
Zenas BioPharma (ZBIO) was downgraded by Zacks Research from "hold" to "strong sell".
3/17
12:30 pm
zbio
Zenas BioPharma (ZBIO) had its price target lowered by Citigroup Inc. from $43.00 to $41.00. They now have a "buy" rating on the stock.
Low
Report
Zenas BioPharma (ZBIO) had its price target lowered by Citigroup Inc. from $43.00 to $41.00. They now have a "buy" rating on the stock.
3/17
08:01 am
zbio
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
Low
Report
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
3/17
08:01 am
zbio
Zenas BioPharma (ZBIO) had its price target raised by Morgan Stanley from $19.00 to $21.00. They now have an "equal weight" rating on the stock.
Low
Report
Zenas BioPharma (ZBIO) had its price target raised by Morgan Stanley from $19.00 to $21.00. They now have an "equal weight" rating on the stock.
3/17
04:47 am
zbio
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares [Yahoo! Finance]
Low
Report
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares [Yahoo! Finance]
3/16
09:04 pm
zbio
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by Guggenheim.
Low
Report
Zenas BioPharma (ZBIO) had its "buy" rating reaffirmed by Guggenheim.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/16
08:29 am
zbio
Form DEFA14A Zenas BioPharma, Inc.
Low
Report
Form DEFA14A Zenas BioPharma, Inc.
3/16
08:27 am
zbio
Form ARS Zenas BioPharma, Inc. For: Dec 31
Low
Report
Form ARS Zenas BioPharma, Inc. For: Dec 31
3/16
08:26 am
zbio
Form DEF 14A Zenas BioPharma, Inc. For: May 11
Low
Report
Form DEF 14A Zenas BioPharma, Inc. For: May 11
3/16
07:27 am
zbio
Form 10-K Zenas BioPharma, Inc. For: Dec 31
Low
Report
Form 10-K Zenas BioPharma, Inc. For: Dec 31
3/16
07:17 am
zbio
Form 8-K Zenas BioPharma, Inc. For: Mar 16
Low
Report
Form 8-K Zenas BioPharma, Inc. For: Mar 16
2/13
05:36 pm
zbio
Form 4 Zenas BioPharma, Inc. For: Feb 11 Filed by: Lu Hongbo
Low
Report
Form 4 Zenas BioPharma, Inc. For: Feb 11 Filed by: Lu Hongbo
2/13
05:06 pm
zbio
Form 4 Zenas BioPharma, Inc. For: Feb 12 Filed by: Allen Patricia L
Low
Report
Form 4 Zenas BioPharma, Inc. For: Feb 12 Filed by: Allen Patricia L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: